Pharosyn raises $3M to cut pharma competitive intelligence from four hours to fifteen minutes

Pharosyn (London) has raised $3 million (approximately €2.5 million) in a pre-seed round led by Moonfire Ventures, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company was founded in 2025 by Stephen Cowley (CEO) and Joshua Hampson, both Cambridge graduates — Cowley in AI research, Hampson in biochemistry.

Pharosyn builds AI-powered competitive intelligence infrastructure specifically for biopharma commercial teams. Its platform monitors clinical trial registries, regulatory databases, and commercial data sources in real time, then synthesises the relevant signals into structured strategic reports tailored to a company's own pipeline. The headline metric: a report that previously took a trained analyst four hours to produce can be generated in fifteen minutes.

A narrow problem, precisely automated

Pharmaceutical competitive intelligence is a recurring, labour-intensive workflow. A commercial team evaluating a competitor's Phase III readout needs to cross-reference the trial design with regulatory precedent, competitive pricing in the same indication, market access patterns in key geographies, and whatever the competitor's investor communications have revealed about their commercial plans. That synthesis is systematic enough to benefit from automation but requires enough domain-specific context — clinical and regulatory conventions, reimbursement logic, therapeutic area dynamics — that generic AI tools handle it inconsistently.

Pharosyn's claim is that its infrastructure is purpose-built for that context: trained on the data types biopharma teams actually rely on, and structured to produce outputs in the format that commercial and portfolio teams use. The 94% reduction in production time is the first measurable proof. Whether it holds across the range of queries a real pharma commercial team generates — from quick competitive snapshots to full due-diligence landscapes — is what the next contracts will establish.

Moonfire back for a second Cambridge bet

Moonfire Ventures has backed Cambridge-founded technical teams before: its investment in MokN (Paris, €12.9M Series A, GV-led) established the fund's track record in enterprise AI security. Pharosyn is a different sector but a recognisable pattern — a two-person Cambridge team with deep technical credentials solving a domain-specific problem that general-purpose AI has not yet commoditised.

The pre-seed capital funds team growth beyond the current eleven members, prioritising engineers and pharmaceutical industry specialists. At this stage, the commercial test is straightforward: can Pharosyn convert its current proof-of-concept speed metrics into signed enterprise contracts, and then into repeat usage that justifies the infrastructure cost? The $3M gives the team enough runway to find out.